![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MSR1 |
Gene summary for MSR1 |
![]() |
Gene information | Species | Human | Gene symbol | MSR1 | Gene ID | 4481 |
Gene name | macrophage scavenger receptor 1 | |
Gene Alias | CD204 | |
Cytomap | 8p22 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P21757 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4481 | MSR1 | HCC2 | Human | Liver | HCC | 1.24e-04 | 1.36e+00 | 0.5341 |
4481 | MSR1 | Pt13.a | Human | Liver | HCC | 2.14e-02 | 1.47e-01 | 0.021 |
4481 | MSR1 | Pt13.c | Human | Liver | HCC | 3.11e-08 | 4.80e-01 | 0.0076 |
4481 | MSR1 | Pt14.d | Human | Liver | HCC | 3.79e-19 | 5.10e-01 | 0.0143 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005123521 | Liver | HCC | maintenance of location | 185/7958 | 327/18723 | 1.70e-07 | 3.12e-06 | 185 |
GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
GO:00199152 | Liver | HCC | lipid storage | 53/7958 | 87/18723 | 4.01e-04 | 2.71e-03 | 53 |
GO:000686921 | Liver | HCC | lipid transport | 198/7958 | 398/18723 | 1.92e-03 | 9.78e-03 | 198 |
GO:00303012 | Liver | HCC | cholesterol transport | 65/7958 | 117/18723 | 2.95e-03 | 1.38e-02 | 65 |
GO:00108832 | Liver | HCC | regulation of lipid storage | 35/7958 | 57/18723 | 3.08e-03 | 1.43e-02 | 35 |
GO:00159182 | Liver | HCC | sterol transport | 71/7958 | 130/18723 | 3.49e-03 | 1.58e-02 | 71 |
GO:0010878 | Liver | HCC | cholesterol storage | 15/7958 | 21/18723 | 7.03e-03 | 2.80e-02 | 15 |
GO:00107422 | Liver | HCC | macrophage derived foam cell differentiation | 24/7958 | 38/18723 | 8.20e-03 | 3.22e-02 | 24 |
GO:00900772 | Liver | HCC | foam cell differentiation | 24/7958 | 38/18723 | 8.20e-03 | 3.22e-02 | 24 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414521 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
hsa0414531 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MSR1 | SNV | Missense_Mutation | novel | c.373N>G | p.Ile125Val | p.I125V | P21757 | protein_coding | tolerated(0.15) | benign(0.24) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MSR1 | SNV | Missense_Mutation | novel | c.250N>C | p.Ser84Pro | p.S84P | P21757 | protein_coding | deleterious(0.02) | benign(0.043) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
MSR1 | SNV | Missense_Mutation | novel | c.1187N>C | p.Val396Ala | p.V396A | P21757 | protein_coding | tolerated(0.3) | benign(0.015) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MSR1 | SNV | Missense_Mutation | novel | c.829N>T | p.Pro277Ser | p.P277S | P21757 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MSR1 | SNV | Missense_Mutation | novel | c.699A>C | p.Gln233His | p.Q233H | P21757 | protein_coding | tolerated(0.1) | benign(0.026) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MSR1 | SNV | Missense_Mutation | rs755140847 | c.116G>A | p.Ser39Asn | p.S39N | P21757 | protein_coding | tolerated(0.06) | benign(0.031) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MSR1 | SNV | Missense_Mutation | c.289C>T | p.Leu97Phe | p.L97F | P21757 | protein_coding | tolerated(0.14) | benign(0.015) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
MSR1 | SNV | Missense_Mutation | rs200576411 | c.55N>A | p.Glu19Lys | p.E19K | P21757 | protein_coding | deleterious(0.01) | benign(0.353) | TCGA-DF-A2KV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MSR1 | SNV | Missense_Mutation | novel | c.609N>T | p.Glu203Asp | p.E203D | P21757 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MSR1 | SNV | Missense_Mutation | novel | c.300N>C | p.Lys100Asn | p.K100N | P21757 | protein_coding | deleterious(0.02) | possibly_damaging(0.526) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4481 | MSR1 | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | H2O2 | 15316030 |
Page: 1 |